MX2021003606A - Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. - Google Patents

Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.

Info

Publication number
MX2021003606A
MX2021003606A MX2021003606A MX2021003606A MX2021003606A MX 2021003606 A MX2021003606 A MX 2021003606A MX 2021003606 A MX2021003606 A MX 2021003606A MX 2021003606 A MX2021003606 A MX 2021003606A MX 2021003606 A MX2021003606 A MX 2021003606A
Authority
MX
Mexico
Prior art keywords
type
biphenyl
treatment
sulfonamide compounds
collagen diseases
Prior art date
Application number
MX2021003606A
Other languages
English (en)
Spanish (es)
Inventor
Radko Komers
Celia Jenkinson
Original Assignee
Travere Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68318947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021003606(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Travere Therapeutics Inc filed Critical Travere Therapeutics Inc
Publication of MX2021003606A publication Critical patent/MX2021003606A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2021003606A 2018-10-04 2019-10-03 Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. MX2021003606A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862741270P 2018-10-04 2018-10-04
US201962853904P 2019-05-29 2019-05-29
US201962894559P 2019-08-30 2019-08-30
PCT/US2019/054559 WO2020072814A1 (en) 2018-10-04 2019-10-03 Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases

Publications (1)

Publication Number Publication Date
MX2021003606A true MX2021003606A (es) 2021-08-16

Family

ID=68318947

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003606A MX2021003606A (es) 2018-10-04 2019-10-03 Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.

Country Status (13)

Country Link
US (1) US11207299B2 (cg-RX-API-DMAC10.html)
EP (1) EP3860594B1 (cg-RX-API-DMAC10.html)
JP (2) JP7524167B2 (cg-RX-API-DMAC10.html)
KR (1) KR102902972B1 (cg-RX-API-DMAC10.html)
CN (1) CN113286587A (cg-RX-API-DMAC10.html)
AU (1) AU2019354784B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021006132A2 (cg-RX-API-DMAC10.html)
CA (1) CA3114434A1 (cg-RX-API-DMAC10.html)
ES (1) ES3057657T3 (cg-RX-API-DMAC10.html)
IL (2) IL327175A (cg-RX-API-DMAC10.html)
MA (1) MA53817A (cg-RX-API-DMAC10.html)
MX (1) MX2021003606A (cg-RX-API-DMAC10.html)
WO (1) WO2020072814A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019530713A (ja) 2016-10-13 2019-10-24 レトロフィン， インコーポレイテッド 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
WO2022246200A1 (en) * 2021-05-21 2022-11-24 Travere Therapeutics, Inc. Methods of treating kidney diseases or disorders
WO2022266370A1 (en) * 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
JP2025183466A (ja) * 2022-11-11 2025-12-17 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID26984A (id) 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2001044239A2 (en) 1999-12-15 2001-06-21 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2010114801A1 (en) 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
WO2010135350A2 (en) 2009-05-20 2010-11-25 Pharmacopeia, Llc Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist
US9719981B2 (en) 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
US10744178B2 (en) * 2014-08-21 2020-08-18 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of disease
CN109982718A (zh) * 2016-09-19 2019-07-05 阿托恩波罗斯生命科学 基于环糊精的聚合物、方法、组合物及其应用
JP2019530713A (ja) * 2016-10-13 2019-10-24 レトロフィン， インコーポレイテッド 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
BR112021012226A2 (pt) 2018-12-21 2021-09-08 Travere Therapeutics, Inc. Composições de esparsentano amorfo

Also Published As

Publication number Publication date
CA3114434A1 (en) 2020-04-09
ES3057657T3 (en) 2026-03-03
KR102902972B1 (ko) 2025-12-22
KR20210081338A (ko) 2021-07-01
AU2019354784A1 (en) 2021-04-15
US11207299B2 (en) 2021-12-28
IL281965B2 (en) 2026-08-01
AU2019354784B2 (en) 2025-07-10
EP3860594A1 (en) 2021-08-11
JP2022514152A (ja) 2022-02-10
MA53817A (fr) 2021-08-11
JP2024133735A (ja) 2024-10-02
IL281965A (en) 2021-05-31
US20200147050A1 (en) 2020-05-14
WO2020072814A1 (en) 2020-04-09
BR112021006132A2 (pt) 2021-07-20
EP3860594B1 (en) 2025-10-01
JP7524167B2 (ja) 2024-07-29
IL281965B1 (en) 2026-04-01
CN113286587A (zh) 2021-08-20
IL327175A (en) 2026-05-01

Similar Documents

Publication Publication Date Title
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
DOP2023000251A (es) Compuestos oligoméricos que inhiben la expresión de hsd17b13
MX2022000143A (es) Metodos novedosos.
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
UY37182A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CO2022005999A2 (es) Inhibidores del factor d del complemento para administración oral
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
ECSP22036455A (es) Inhibidores del factor d del complemento para administraci?n oral
PY1944026A (es) Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
MX2016011115A (es) Terapia inmunorreguladora contra autoinmunidad en diabetes tipo 1.
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
CO2023017669A2 (es) Terapia combinada anti-vhc ventajosa
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX2021014523A (es) Metodos para tratar colangiocarcinoma.
MX2022002838A (es) Compuesto heterocíclico aromático que tiene estructura tricíclica, y método de preparación y aplicación del mismo.
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1